SLE, active renal disease | SLE, non-active renal disease | Diabetic nepharopathy | ANCA associated vasculitis | |
---|---|---|---|---|
Number | 19 | 79 | 74 | 11 |
Female/male, number | 17/2 | 71/8 | 6/8 | 4/7 |
Age, years | 31 (19 to 60) | 44 (21 to 72) | 58 (27 to 93) | 63 (38 to 78) |
SLEDAI | 14 (11 to 23) | 2 (0 to 10) | na | na |
BVAS | na | na | na | 5 (0 to 16) |
Immunosuppresive treatment | 19 × Pred 7 × Cyc, 1 × Aza 13 × HCQ, 2 × MMF | 62 × Pred, 20 × Aza, 37 × HcQ, 15 × MMF, 3 × MTX, 3 xBelim, 1 × Flebo | 1 × Rtx | 9 × Pred, 1 × Cyc, 6 × Aza, 2 x Rtx |
Prednisolone dose, mg, median (IQR) | 40 (30 to 50) | 5.0 (5.0 to 7.5) | - | 5.0 (2.5 to 5.0) |